Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The vast majority of tobacco smokers seeking to quit will relapse within the first month of abstinence. Currently available smoking cessation agents have limited utility in increasing rates of smoking cessation and in some cases there are notable safety concerns related to their use. Hence, there is a pressing need to develop safer and more efficacious smoking cessation medications. METHODS: Here, we provide an overview of current efforts to develop new pharmacotherapeutic agents to facilitate smoking cessation, identified from ongoing clinical trials and published reports. RESULTS: Nicotine is considered the major addictive agent in tobacco smoke, and the vast majority of currently available smoking cessation agents act by modulating nicotinic acetylcholine receptor (nAChR) signaling. Accordingly, there is much effort directed toward developing novel small molecule therapeutics and biological agents such as nicotine vaccines for smoking cessation that act by modulating nAChR activity. Our increasing knowledge of the neurobiology of nicotine addiction has revealed new targets for novel smoking cessation therapeutics. Indeed, we highlight many examples of novel small molecule drug development around non-nAChR targets. Finally, there is a growing appreciation that medications already approved for other disease indications could show promise as smoking cessation agents, and we consider examples of such repurposing efforts. CONCLUSION: Ongoing clinical assessment of potential smoking cessation agents offers the promise of new effective medications. Nevertheless, much of our current knowledge of molecular mechanisms of nicotine addiction derived from preclinical studies has not yet been leveraged for medications development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523 · cited 2×
“, 2008; Wang, Broderick, Matakidou, Eisen, & Houlston, 2010), likely reflecting higher levels of tobacco dependence in individuals carrying risk alleles and consequently greater exposure to carcinogens contained in tobacco smoke (Le Marchand et al., 2008; Thorgeirsson et al., 2008).”
BackgroundPicciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 1×
“brain, abolishes sensitivity to the reinforcing effects of nicotine (Picciotto et al., 1998).”
BackgroundAmos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008) · Nature Genetics · doi:10.1038/ng.109 · Cited by 1,310
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., et al. (2008) · Nature · doi:10.1038/nature06885 · Cited by 1,275 · cited 2×
“The D398N allele is also a major risk factor for lung cancer and COPD in smokers (Amos et al., 2008; Hung et al., 2008; Wang, Broderick, Matakidou, Eisen, & Houlston, 2010), likely reflecting higher levels of tobacco dependence in individuals carrying risk alleles and consequently greater…”
BackgroundEstimates of global mortality attributable to smoking in 2000
Ezzati, M., & Lopez, A. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14338-3 · Cited by 1,247 · cited 1×
“…billion current smokers worldwide will die from smoking-related illnesses, such as chronic obstructive pulmonary disorder (COPD), lung cancer, and cardiovascular disease (Besson et al., 2012; Coe et al., 2005; Doll, Peto, Boreham, & Sutherland, 2004; Ezzati & Lopez, 2003; Mathers & Loncar, 2006).”
BackgroundDamage to the insula disrupts addiction to cigarette smoking
Naqvi, N. H., Rudrauf, D., Damasio, H., & Bechara, A. (2007) · Science · doi:10.1126/science.1135926 · Cited by 1,245
Genome-wide meta-analyses identify multiple loci associated with smoking behavior
The Tobacco and Genetics Consortium (2010) · Nature Genetics · doi:10.1038/ng.571 · Cited by 1,098
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979 · cited 1×
“Nevertheless, ~80% of smokers attempting to quit will relapse within the first month of abstinence (Benowitz, 2009).”
BackgroundThe habenula: from stress evasion to value-based decision-making
Hikosaka, O. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2866 · Cited by 955
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 1×
“…billion current smokers worldwide will die from smoking-related illnesses, such as chronic obstructive pulmonary disorder (COPD), lung cancer, and cardiovascular disease (Besson et al., 2012; Coe et al., 2005; Doll, Peto, Boreham, & Sutherland, 2004; Ezzati & Lopez, 2003; Mathers & Loncar, 2006).”
BackgroundFlores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl438 · Cited by 850 · cited 1×
“Allelic variation in the CHRNA5-CHRNA3-CHRNB4 subunit gene cluster located in chromosome region 15q25, which encodes the α5, α3, β4 nAChR subunits, respectively, significantly increases risk of tobacco addiction (Berrettini et al., 2008; Bierut et al., 2008; Hung et al., 2008; Lips et al., 2009; Saccone et al., 2007;…”
BackgroundChromatin Remodeling Is a Key Mechanism Underlying Cocaine-Induced Plasticity in Striatum
Kumar, A., Choi, K.-H., Renthal, W., Tsankova, N. M., Theobald, D. E. H., Truong, H.-T., Russo, S. J., LaPlant, Q., Sasaki, T. S., Whistler, K. N., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.023 · Cited by 764
Jhou, T. C., Fields, H. L., Baxter, M. G., Saper, C. B., & Holland, P. C. (2009) · Neuron · doi:10.1016/j.neuron.2009.02.001 · Cited by 696
Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior
The ENGAGE Consortium, Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.573 · Cited by 689 · cited 4×
“Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.”
BackgroundInfluentialNicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
Tapper, A. R., McKinney, S. L., Nashmi, R., Schwarz, J., Deshpande, P., Labarca, C., Whiteaker, P., Marks, M. J., Collins, A. C., & Lester, H. A. (2004) · Science · doi:10.1126/science.1099420 · Cited by 686
Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity
Maze, I., Covington, H. E., Dietz, D. M., LaPlant, Q., Renthal, W., Russo, S. J., Mechanic, M., Mouzon, E., Neve, R. L., Haggarty, S. J., et al. (2010) · Science · doi:10.1126/science.1179438 · Cited by 665
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake
Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J., & Kenny, P. J. (2011) · Nature · doi:10.1038/nature09797 · Cited by 663 · cited 3×
“…MHb or the IPN using the local anesthetic lidocaine or disruption of NMDA receptor-mediated glutamatergic transmission in these sites using the competitive antagonist LY2358959 increased nicotine self-administration in rats in a manner similar to the α5 nAChR subunit KO mice (Fowler et al., 2011).”
MethodResultSelf-citationVariants in Nicotinic Receptors and Risk for Nicotine Dependence
Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Grucza, R. A., Xuei, X., Saccone, N. L., Saccone, S. F., Bertelsen, S., Fox, L., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111711 · Cited by 648 · cited 8×
“Hence, it is an interesting prospect that galantamine and other putative α5* nAChR PAMs may have clinical utility for smoking cessation, particularly in those individuals carrying CHRNA5 risk alleles that result in decreased function of α5* nAChRs (Bierut et al., 2008).”
BackgroundInfluentialDnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens
LaPlant, Q., Vialou, V., Covington, H. E., Dumitriu, D., Feng, J., Warren, B. L., Maze, I., Dietz, D. M., Watts, E. L., Iñiguez, S. D., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2619 · Cited by 612
Histone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli
Renthal, W., Maze, I., Krishnan, V., Covington, H. E., Xiao, G., Kumar, A., Russo, S. J., Graham, A., Tsankova, N., Kippin, T. E., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.032 · Cited by 599
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Maskos, U., Molles, B. E., Pons, S., Besson, M., Guiard, B. P., Guilloux, J.-P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., et al. (2005) · Nature · doi:10.1038/nature03694 · Cited by 566 · cited 2×
“The stimulatory effect of nicotine on midbrain dopamine transmission is considered central to its reinforcing properties that contribute to the development and maintenance of the tobacco habit (Exley et al., 2011; Maskos et al., 2005; Pons et al., 2008).”
BackgroundVarenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Representation of negative motivational value in the primate lateral habenula
Matsumoto, M., & Hikosaka, O. (2009) · Nature Neuroscience · doi:10.1038/nn.2233 · Cited by 547 · cited 2×
“…densely to the rostromedial tegmental nucleus (RMTg) (Jhou, Fields, Baxter, Saper, & Holland, 2009) and has a well-established inhibitory effect on the firing of midbrain dopamine neurons (Bromberg-Martin & Hikosaka, 2011; Hikosaka, 2010; Lecourtier & Kelly, 2007; Matsumoto & Hikosaka, 2009).”
BackgroundBupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking
Berrettini, W., Yuan, X., Tozzi, F., Song, K., Francks, C., Chilcoat, H., Waterworth, D., Muglia, P., & Mooser, V (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002154 · Cited by 465
Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors
Nelson, M. E., Kuryatov, A., Choi, C. H., Zhou, Y., & Lindstrom, J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.332 · Cited by 422
Le Novère, N., Corringer, P., & Changeux, J. (2002) · Journal of Neurobiology · doi:10.1002/neu.10153 · Cited by 411
Genome-wide Analysis of Chromatin Regulation by Cocaine Reveals a Role for Sirtuins
Renthal, W., Kumar, A., Xiao, G., Wilkinson, M., Covington, H. E., Maze, I., Sikder, D., Robison, A. J., LaPlant, Q., Dietz, D. M., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.026 · Cited by 409
Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., & Gotti, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08785.2002 · Cited by 407
Le Novere, N., Zoli, M., & Changeux, J. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01206.x · Cited by 385
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Ren, J., Qin, C., Hu, F., Tan, J., Qiu, L., Zhao, S., Feng, G., & Luo, M. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.038 · Cited by 315 · cited 1×
“…most MHb neurons also produce and co-release glutamate, with this excitatory neurotransmitter considered the major functional transmitter at the MHb-IPN synapse (Girod, Barazangi, McGehee, & Role, 2000; Mata, Schrier, & Moore, 1977; Ren et al., 2011; Vincent, Staines, McGeer, & Fibiger, 1980).”
BackgroundPons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J. M., Changeux, J. P., Maskos, U., & Fratta, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3918-08.2008 · Cited by 312 · cited 3×
“…selfadministration procedure in which mice are restrained but can nose-poke for intravenous nicotine infusions via a catheter in the tail vein during a single session, it was shown that α6 subunit KO mice had attenuated levels of nicotine intake compared with wildtype mice (Pons et al., 2008).”
BackgroundMethodNeurobiology of the nicotine withdrawal syndrome
Kenny, P. J., & Markou, A. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00651-7 · Cited by 310 · cited 4×
“For example, medications designed to limit weight gain or reduce anxiety, restlessness, or irritability during withdrawal may facilitate abstinence from tobacco smoking (Kenny & Markou, 2001).”
BackgroundInfluentialSelf-citationInactivation of the Interoceptive Insula Disrupts Drug Craving and Malaise Induced by Lithium
Contreras, M., Ceric, F., & Torrealba, F. (2007) · Science · doi:10.1126/science.1145590 · Cited by 297
Insular hypocretin transmission regulates nicotine reward
Hollander, J. A., Lu, Q., Cameron, M. D., Kamenecka, T. M., & Kenny, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808023105 · Cited by 296
Self-citationLecourtier, L., & Kelly, P. H. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.01.004 · Cited by 283 · cited 4×
“The habenula is a diencephalic structure located on the dorsomedial surface of the caudal thalamus that is segregated into medial (MHb) and lateral (LHb) domains (Hikosaka, 2010; Lecourtier & Kelly, 2007).”
BackgroundInfluentialFrahm, S., Ślimak, M. A., Ferrarese, L., Santos-Torres, J., Antolin-Fontes, B., Auer, S., Filkin, S., Pons, S., Fontaine, J.-F., Tsetlin, V., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.013 · Cited by 283
Lateral habenula neurons signal errors in the prediction of reward information
Bromberg-Martin, E. S., & Hikosaka, O. (2011) · Nature Neuroscience · doi:10.1038/nn.2902 · Cited by 275
Weiss, R. B., Baker, T. B., Cannon, D. S., von Niederhausern, A., Dunn, D. M., Matsunami, N., Singh, N. A., Baird, L., Coon, H., McMahon, W. M., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000125 · Cited by 271 · cited 1×
“…to tobacco dependence, the D398N major risk allele is associated with heavy smoking (Berrettini et al., 2008; Bierut et al., 2008; Grucza et al., 2008; Stevens et al., 2008), early onset of smoking behavior (Weiss et al., 2008) and with “pleasurable buzz” from tobacco (Sherva et al., 2008).”
BackgroundNicotine: from molecular mechanisms to behaviour
Wonnacott, S., Sidhpura, N., & Balfour, D. J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.12.002 · Cited by 263
Nicotine addiction: the possible role of functional upregulation
Buisson, B., & Bertrand, D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01979-9 · Cited by 254 · cited 1×
“Nicotinic receptors containing α4 and β2 subunits (denoted as α4β2* nAChRs) are the most prevalent in the CNS (Flores, Rogers, Pabreza, Wolfe, & Kellar, 1992) and are considered the major subtype involved in regulating the addiction-relevant actions of nicotine (Buisson & Bertrand, 2002).”
BackgroundThe subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum
Grady, S. R., Salminen, O., Laverty, D. C., Whiteaker, P., McIntosh, J. M., Collins, A. C., & Marks, M. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.032 · Cited by 252 · cited 2×
“As noted above, α6* nAChRs are also believed to contribute to the stimulatory effects of nicotine on striatal dopamine transmission (Grady et al., 2007).”
BackgroundGeorge, O., Ghozland, S., Azar, M. R., Cottone, P., Zorrilla, E. P., Parsons, L. H., O'Dell, L. E., Richardson, H. N., & Koob, G. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707585104 · Cited by 245 · cited 1×
“It is important to note, however, that other brain circuits not considered here are also likely to play a role in tobacco dependence independent of nicotine reinforcement, such as the extended amygdala and its involvement in withdrawal-induced increases in nicotine consumption (George et al., 2007).”
BackgroundGotti, C., Guiducci, S., Tedesco, V., Corbioli, S., Zanetti, L., Moretti, M., Zanardi, A., Rimondini, R., Mugnaini, M., Clementi, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5095-09.2010 · Cited by 226
Saccone, N. L., Saccone, S. F., Hinrichs, A. L., Stitzel, J. A., Duan, W., Pergadia, M. L., Agrawal, A., Breslau, N., Grucza, R. A., Hatsukami, D., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30828 · Cited by 215
Zwart, R., & Vijverberg, H. P. M. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.6.1124 · Cited by 215
Substance P containing and cholinergic projections from the habenula
Claudio Cuello, A., Emson, P. C., Paxinos, G., & Jessell, T. (1978) · Brain Research · doi:10.1016/0006-8993(78)90484-5 · Cited by 197
Roles of Accessory Subunits in α4β2* Nicotinic Receptors
Kuryatov, A., Onksen, J., & Lindstrom, J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046789 · Cited by 195
Liechti, M. E., Lhuillier, L., Kaupmann, K., & Markou, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-07.2007 · Cited by 193
Nicotinic Receptor Gene Variants Influence Susceptibility to Heavy Smoking
Stevens, V. L., Bierut, L. J., Talbot, J. T., Wang, J. C., Sun, J., Hinrichs, A. L., Thun, M. J., Goate, A., & Calle, E. E. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0585 · Cited by 190
Schlaepfer, I. R., Hoft, N. R., Collins, A. C., Corley, R. P., Hewitt, J. K., Hopfer, C. J., Lessem, J. M., McQueen, M. B., Rhee, S. H., & Ehringer, M. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.024 · Cited by 186 · cited 1×
“, 2009) and rs1948 in the β4 subunit gene (Schlaepfer et al., 2008).”
Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162 · cited 1×
“Similarly, the α4β2* nAChR partial agonist dianicline (SSR-591,813), developed by SanofiAventis for smoking cessation, is less efficacious than varenicline likely because of its poorer brain penetration properties (Rollema et al., 2010).”
BackgroundExley, R., Maubourguet, N., David, V., Eddine, R., Evrard, A., Pons, S., Marti, F., Threlfell, S., Cazala, P., McIntosh, J. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103000108 · Cited by 159 · cited 14×
“In particular, the actions of nicotine at α4β2* nAChRs in the VTA are believed to play a key role in the reinforcing effects of the drug that motivate the establishment and maintenance of the tobacco habit.”
BackgroundMethodResultInfluentialGranular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction
Forget, B., Pushparaj, A., & Le Foll, B. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.029 · Cited by 153
A Risk Allele for Nicotine Dependence in CHRNA5 Is a Protective Allele for Cocaine Dependence
Grucza, R. A., Wang, J. C., Stitzel, J. A., Hinrichs, A. L., Saccone, S. F., Saccone, N. L., Bucholz, K. K., Cloninger, C. R., Neuman, R. J., Budde, J. P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.018 · Cited by 152
Lips, E. H., Gaborieau, V., McKay, J. D., Chabrier, A., Hung, R. J., Boffetta, P., Hashibe, M., Zaridze, D., Szeszenia-Dabrowska, N., Lissowska, J., et al. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyp288 · Cited by 145 · cited 1×
“Allelic variation in the CHRNA5-CHRNA3-CHRNB4 subunit gene cluster located in chromosome region 15q25, which encodes the α5, α3, β4 nAChR subunits, respectively, significantly increases risk of tobacco addiction (Berrettini et al., 2008; Bierut et al., 2008; Hung et al., 2008; Lips et al., 2009; Saccone et al., 2007;…”
BackgroundSherva, R., Wilhelmsen, K., Pomerleau, C. S., Chasse, S. A., Rice, J. P., Snedecor, S. M., Bierut, L. J., Neuman, R. J., & Pomerleau, O. F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02279.x · Cited by 143
Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors
Girod, R., Barazangi, N., McGehee, D., & Role, L. W. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00145-3 · Cited by 122
Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS
Sugama, S., Cho, B. P., Baker, H., Joh, T. H., Lucero, J., & Conti, B. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03363-2 · Cited by 102
Brunzell, D. H., Boschen, K. E., Hendrick, E. S., Beardsley, P. M., & McIntosh, J. M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.171 · Cited by 95
Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
De Biasi, M., & Salas, R. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-mr-355 · Cited by 95 · cited 10×
“These findings suggest that the MHb-IPN system regulates aspects of the aversive properties of nicotine such that deficits in the responsiveness of this circuit may diminish nicotine aversion and increase vulnerability to tobacco dependence.”
BackgroundInfluentialMugnaini, M., Tessari, M., Tarter, G., Merlo Pich, E., Chiamulera, C., & Bunnemann, B. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02220.x · Cited by 88 · cited 1×
“The MHb contains some of the highest densities of nicotine binding sites in brain (Mugnaini et al., 2002).”
BackgroundAdverse effects and tolerability of medications for the treatment of tobacco use and dependence
Hays, J. T., & Ebbert, J. O. (2010) · Drugs · doi:10.2165/11538190-000000000-00000 · Cited by 74 · cited 1×
“…labeling because of reported serious mental-health events associated with their use, with issues related to tolerability and compliance also representing limitations in their use (Catz et al., 2011; Hays & Ebbert, 2010; Oncken et al., 2006; Zhao, Schwam, Fullerton, O’Gorman, & Burstein, 2011).”
BackgroundTransmitters contained in the efferents of the habenula
Vincent, S. R., Staines, W. A., McGeer, E. G., & Fibiger, H. C. (1980) · Brain Research · doi:10.1016/0006-8993(80)90084-0 · Cited by 74
Tobacco dependence, the insular cortex and the hypocretin connection
Kenny, P. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.08.015 · Cited by 69
Self-citationLevin, E. D., Rezvani, A. H., Xiao, Y., Slade, S., Cauley, M., Wells, C., Hampton, D., Petro, A., Rose, J. E., Brown, M. L., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162073 · Cited by 65
Eckenrode, T. C., Barr, G. A., Battisti, W. P., & Murray, M. (1987) · Brain Research · doi:10.1016/0006-8993(87)90095-3 · Cited by 64
Anderson, D. J., Malysz, J., Grønlien, J. H., El Kouhen, R., Håkerud, M., Wetterstrand, C., Briggs, C. A., & Gopalakrishnan, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.024 · Cited by 44 · cited 6×
“Interestingly, varenicline-induced increases in dopamine release from striatal or prefrontal cortical tissues was unaffected by the α3/α6β2* selective antagonist CntxMII (Anderson et al., 2009), consistent with the largely α4β2 nAChR-specific actions of varenicline and suggesting that α6* nAChRs are unlikely to play a…”
BackgroundInfluentialMata, M. M., Schrier, B. K., & Moore, R. Y. (1977) · Experimental Neurology · doi:10.1016/0014-4886(77)90116-9 · Cited by 33
Cited by
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“Owing to the serendipitous observation that it decreased smoking in depressed patients taking this drug, Bupropion was approved for smoking cessation in 1997 (Harmey et al., 2012).”
BackgroundNicotine Replacement Therapy : An Overview
Wadgave, U., & L., N. (2016) · International Journal of Health Sciences · doi:10.12816/0048737 · Cited by 141
The CHRNA5–A3–B4 Gene Cluster and Smoking: From Discovery to Therapeutics
Lassi, G., Taylor, A. E., Timpson, N. J., Kenny, P. J., Mather, R. J., Eisen, T., & Munafò, M. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.10.005 · Cited by 85
Self-citationNicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum
Wolfman, S. L., Gill, D. F., Bogdanic, F., Long, K., Al-Hasani, R., McCall, J. G., Bruchas, M. R., & McGehee, D. S. (2018) · Nature Communications · doi:10.1038/s41467-018-04654-2 · Cited by 81
Formatting biological big data for modern machine learning in drug discovery
Duran‐Frigola, M., Fernández‐Torras, A., Bertoni, M., & Aloy, P. (2019) · WIREs Computational Molecular Science · doi:10.1002/wcms.1408 · Cited by 25
Metadata
- Authors
- Harmey, D., Griffin, P. R., & Kenny, P. J.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-27
- Volume
- 14
- Issue
- 11
- Pages
- 1300-1318
- ISSN
- 1462-2203 (ISSN-L)
- 1469-994X
- OpenAlex
- W2031417710
- Cited by
- 37
- References
- 73
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.